Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C C Fu

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 10, 2019
[Allogeneic CAR-T for treatment of relapsed and/or refractory multiple myeloma: four cases report and literatures review]L Z Yan, J J Shang, X L Shi, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 28, 2023
[Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma]W Q Yao, L Z Yan, J J Shang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 9, 2022
[A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis]Y Liu, H Y You, L Z Yan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 30, 2018
[Safety and efficacy of chimeric antigen receptor T cell in the treatment of elderly patients with hematological malignancies]D Liu, P Ke, L Huo, et al.
Zhonghua Nei Ke Za Zhi|April 1, 2016
[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib]B Gu, G H Chen, H J Shen, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 4, 2017
[Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center]M Y Li, H Y Chao, A N Sun, et al.
Diabetes Care|January 1, 1993
Development of macrovascular diseases in NIDDM patients in northern Taiwan. A 4-yr follow-up studyC C Fu, C J Chang, C H Tseng, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 28, 2023
[Multiple myeloma with chromothripsis: three cases report]C X Wu, Z Zeng, Q R Wang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 24, 2016
[The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma]P F Wang, Y Xu, S Yan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 21, 2016
[Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas]Q L Wang, H W Huang, Z M Jin, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 10, 2019
[Allogeneic CAR-T for treatment of relapsed and/or refractory multiple myeloma: four cases report and literatures review]L Z Yan, J J Shang, X L Shi, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 28, 2023
[Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma]W Q Yao, L Z Yan, J J Shang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 9, 2022
[A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis]Y Liu, H Y You, L Z Yan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 30, 2018
[Safety and efficacy of chimeric antigen receptor T cell in the treatment of elderly patients with hematological malignancies]D Liu, P Ke, L Huo, et al.
Zhonghua Nei Ke Za Zhi|April 1, 2016
[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib]B Gu, G H Chen, H J Shen, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 4, 2017
[Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center]M Y Li, H Y Chao, A N Sun, et al.
Diabetes Care|January 1, 1993
Development of macrovascular diseases in NIDDM patients in northern Taiwan. A 4-yr follow-up studyC C Fu, C J Chang, C H Tseng, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 28, 2023
[Multiple myeloma with chromothripsis: three cases report]C X Wu, Z Zeng, Q R Wang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 24, 2016
[The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma]P F Wang, Y Xu, S Yan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 21, 2016
[Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas]Q L Wang, H W Huang, Z M Jin, et al.
Pageof 8